Lung Cancer

Experts share insight on their clinical experience with interstitial lung disease.

Recently developed treatments for HER2-positive breast cancer, lung cancers, and gastrointestinal cancers include antibody-drug conjugates, CDK4/6 inhibitors, and immuno-oncology agents.

Edward B. Garon, MD, discusses the expanding treatment landscape in lung cancer.

In our exclusive interview, Dr. Levy discusses the challenges of targeting KRAS and highlighted some of the investigational agents directed toward KRAS G12C mutations that have emerged in the NSCLC pipeline.

Treatment with repotrectinib resulted in favorable responses in patients with ROS1- or NTRK-driven tumors, regardless of prior treatment with TKIs, according to interim data from the phase 2 TRIDENT-1 trial.

Paul A. Bunn, Jr MD, discusses potentially targeting HER3 in non–small cell lung cancer.

The FDA has granted a priority review designation to a supplemental biologics license application for a new 4-week, fixed-dose regimen as treatment in approved indications of non–small cell lung cancer and bladder cancer.

The FDA has granted a priority review designation to a new drug application (NDA) for trilaciclib for the treatment of patients with small cell lung cancer (SCLC) who are being treated with chemotherapy.